MDWD MediWound Ltd. - Ordinary Share

-0.03  -0%
Previous Close 7.23
Open 7.20
Price To book 42.01
Market Cap 157.90M
Shares 21,930,000
Volume 20,199
Short Ratio 1.55
Av. Daily Volume 37,405

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released early February 2016. Primary endpoint met. Secondary endpoint of time to complete debridement not met. Top-line data from second cohort due mid-2017. Pivotal trial planned.
Chronic and other hard-to-heal wounds
Phase 3 initiated mid April 2015. Data due 1H 2018.
Severe burns

Latest News

  1. BARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWound’s NexoBrid® Development
  2. Independent Study in Germany Shows NexoBrid® Reduces Average Burn Treatment Costs by nearly 30% Versus Standard of Care
  3. MediWound to Present at the Jefferies Global Healthcare Conference
  4. Poster Presentation Highlighting NexoBrid® Awarded “Best Poster” at the 52nd Congress of the Spanish Society of Aesthetic, Plastic and Reconstructive Surgery
  5. MediWound Announces Changes to its Board of Directors
  6. MediWound Ltd. :MDWD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  7. Edited Transcript of MDWD earnings conference call or presentation 8-May-17 12:30pm GMT
  8. Investor Network: MediWound Ltd. to Host Earnings Call
  9. MediWound reports 1Q loss
  10. MediWound Reports First Quarter 2017 Financial Results
  11. MediWound Announces Successful GMP Manufacturing Audit by the Israeli Ministry of Health
  12. MediWound to Host First Quarter 2017 Financial Results Conference Call on May 8, 2017 at 8:30 a.m. Eastern Time
  13. MediWound’s NexoBrid® and EscharEx® to be Highlighted in Multiple Presentations at the Symposium on Advanced Wound Care Spring
  14. MediWound Ltd. :MDWD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  15. MediWound Ltd. :MDWD-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  16. Edited Transcript of MDWD earnings conference call or presentation 21-Feb-17 1:30pm GMT